Ciliatech
A medical device for glaucoma, designed as a minimally invasive implant to lower intraocular pressure and prevent blindness.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor investor investor | €0.0 | round | |
* | N/A | €1.8m | Debt |
| Total Funding | 000k | ||
Related Content
Ciliatech is a medical technology company specializing in ophthalmology. It is focused on developing a new class of implant for treating glaucoma, a condition that can lead to blindness. The company's main product is the Intercil® (CID), a uveal spacer designed to lower intraocular pressure (IOP) in patients with primary open-angle glaucoma (POAG) and primary angle-closure glaucoma (PACG).
The business model revolves around the development and commercialization of this medical device. Ciliatech's target clients are ophthalmic surgeons and their patients suffering from glaucoma. The company is in the clinical trial phase, with its SAFARI I and II studies demonstrating the safety and efficacy of the implant. The procedure is designed to be minimally invasive, avoiding complications like corneal endothelial cell loss. The company is working towards regulatory approval for its device.
Keywords: ophthalmology, glaucoma treatment, medical device, intraocular pressure, Intercil, minimally invasive surgery, clinical trials, medtech, uveal spacer, POAG